Pain Reform

We are a clinical stage specialty pharmaceutical company
focused on the reformulation of established therapeutics
Our proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for using opiates very often administered post-surgically.

Our strategy is to incorporate generic drugs which have been proven safe and effective with our proprietary extended drug-delivery system in order to create a significant improvement in therapy via extended-release drug products and to take advantage of the 505(b)(2) regulatory pathway created by the U.S. Food and Drug Administration (“FDA”). The 505(b)(2) new drug application (“NDA”) process provides for FDA approval of a new drug based in part on data that was developed by others, including published literature references and data previously reviewed by the FDA in its approval of a separate application. Using this pathway can significantly reduce the future time and costs associated with clinical development.

PRF-110, our first product, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, waterless and clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.